Patent · US Active

1,4 oxazines as BACE1 and/or BACE2 inhibitors

US9242943B2 · kind B2 · utility

0Cited by

3References

17Claims

0Family size

Assignees

SIENA BIOTECH S.P.A. · IT
Hoffmann-La Roche Inc. · US

Inventors

Matteo Andreini · Siena, IT
Emanuele Gabellieri · Lausanne, CH
Wolfgang Guba · Memmingen, DE
Hans Hilpert · Reinach, CH
Alexander V. Mayweg · Basel, CH
Robert Narquizian · La Valette-du-Var, FR
Eoin Power · Siena, IT
Massimiliano Travagli · Siena, IT
Thomas Woltering · Freiburg (Elbe), DE
Wolfgang Wostl · Weil am Rhein, DE
Harald Mauser · Riehen, CH

Key dates

Filing date	Jan 12, 2012
Grant date	Jan 26, 2016
Priority date	—
Expiry date	Jan 12, 2032

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D413/12
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to 1,4 Oxazines of formula Ihaving BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.